- Home
- ISRG vs ABBV Comparison
ISRG vs ABBV Comparison
Compare ISRG & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ISRG | ABBV |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.8B | 375.7B |
| IPO Year | 1998 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ISRG | ABBV |
|---|---|---|
| Price | $460.56 | $208.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 19 |
| Target Price | ★ $598.33 | $250.56 |
| AVG Volume (30 Days) | 1.5M | ★ 4.7M |
| Earning Date | 04-21-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.32% |
| EPS Growth | ★ 22.59 | N/A |
| EPS | ★ 7.87 | 2.36 |
| Revenue | $10,064,700,000.00 | ★ $61,160,000,000.00 |
| Revenue This Year | $16.69 | $11.90 |
| Revenue Next Year | $13.86 | $8.13 |
| P/E Ratio | ★ $59.52 | $88.41 |
| Revenue Growth | ★ 20.51 | 8.57 |
| 52 Week Low | $427.84 | $168.54 |
| 52 Week High | $603.88 | $244.81 |
Technical Indicators
Market Signals| Indicator | ISRG | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 44.41 | 43.58 |
| Support Level | $459.32 | $204.17 |
| Resistance Level | $490.81 | $234.76 |
| Average True Range (ATR) | 10.74 | 5.11 |
| MACD | 2.09 | 0.40 |
| Stochastic Oscillator | 48.73 | 36.44 |
Price Performance
Historical ComparisonAbout ISRG Intuitive Surgical Inc.
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.